We analyzed tandem duplication in the juxtamembrane (JM) domain of the FLT3 (FMS-like tyrosine kinase 3/FLK2, CD135) gene in 94 children with acute myeloid leukemia (AML) and evaluated its correlation with clinical features. Longer polymerase chain reaction (PCR) products were observed in five patients; 1/3 of M0, 1/9 of M1, 1/39 of M2, 1/9 of M3 and 1/12 of M5. The sequence analyses of abnormal PCR products showed that all the abnormal products were derived from tandem duplications involving the JM domain and that all the lengthened sequences were in-frame as we previously reported. Statistical analyses revealed a significantly lower incidence of the tandem duplication in childhood AML patients than in adult patients (P Ͻ 0.05), and significantly shorter disease-free survival in patients with mutant FLT3 than in patients with wild-type FLT3 (P Ͻ 0.05). Our results suggest that the tandem duplication in the JM domain of the FLT3 gene is not a frequent phenomenon but might be a factor of poor prognosis in childhood patients with AML.
Introduction
FLT3 (FMS-like tyrosine kinase 3/FLK2, CD135) is a member of type III receptor tyrosine kinase (RTK), and its structure resembles KIT, FMS and PDGFR.
1 FLT3 is composed of four domains; the extracellular (EC) domain consisting of five immunoglobulin-like (IgL) structures, the transmembrane (TM) domain, the juxtamembrane (JM) domain, and the tyrosine kinase (TK) domains separated by a kinase insert (KI) followed by a carboxyl tail.
2 FLT3 plays an important role with FLT3 ligand (FL) in the early stage of hematopoiesis. Activation of tyrosine kinases and autophosphorylation through dimerization of FLT3 binding FL regulates pluripotent stem cells, early progenitor cells, and immature lymphocytes 3 together with other cytokines, including c-kit ligand. 4 In hematological malignancies expression of the FLT3 gene was observed dominantly both at the mRNA and protein levels in precursor B-ALL, AML, and blast crisis (BC) of chronic myeloid leukemia (CML). 5 As a somatic mutation, we recently found an internal tandem duplication in the JM domain of the FLT3 gene in about 20% of adult patients with AML, and suggested that the mutation might be a factor of poor prognosis in adult AML. 6, 7 We also reported that the mutation is specifically found in AML and myelodysplastic syndrome (MDS), and that accumulation of the duplication may be correlated with a leukemic change of MDS. [6] [7] [8] [9] However, pediatric cases with AML have not been yet studied for the mutation of the FLT3 gene because AML in childhood is not as common as that in adults, and a limited number of groups have performed clinical studies of pediatric AML.
In this report we analyzed the incidence of tandem duplication in the JM domain of the FLT3 gene in childhood AML patients, and evaluated its correlation with clinical features.
Materials and methods

Patients and samples
Ninety-four childhood AML samples were studied. The mean age was 6.8 years old, and sex ratio (male/female) was 58/36. The details are described in Tables 1 and 2 . The diagnosis of these patients was made according to the French-AmericanBritish (FAB) classification. 10 Bone marrow cells were obtained at presentation from these patients after obtaining informed consent. The children with AML were enrolled in the Children's Cancer and Leukemia Study Group (CCLSG) in Japan. They were treated and followed by CCLSG's common protocols: 'ANLL9205', 'ANLL9411P' and 'APL-ATRA proto- col'. In the 'ANLL9205' for AML excluding M3, remission induction therapy (ACV therapy) consisted of vincristine (VCR), pirarubicin (THP), and citarabin (Ara-C). After induction, allo-bone marrow transplantation was considered for patients whose HLA type was matched with a donor, and maintenance therapy on those whose HLA type was not matched. The maintenance therapy consisted of ACV therapy and high-dose Ara-C and etoposide (VP-16). 11 In the 'ANLL9411P' for AML except M3, remission induction therapy consisted of THP, Ara-C and mitoxantron (MIT), and intensification therapy consisted of THP, VP-16, Ara-C and mercaptopurine (6-MP). 12 In the 'APL-ATRA protocol' for M3, remission induction therapy consisted of all-trans retinoic acid (ATRA) and consolidation therapy was with enocitabin (BHAC), daunorubicin (DNR), 6-MP and prednisolone (PSL). In addition, maintenance therapy was carried out by doxorubicin (ADM), cyclophosphamide (CPM), Ara-C, VCR, PSL and ATRA. 13 For those patients who were refractory to conservative therapies or could not be treated with bone marrow transplantation, high-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) was performed. The indication for PBSCT and drugs for the high-dose chemotherapy have been described previously.
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DNA extraction and PCR analysis
Genomic DNA was extracted from bone marrow samples or blood by a standard procedure. 6, 14 Alternatively, DNA was extracted from smears on glass slides. To detect length mutations, these samples were amplified by polymerase chain reaction (PCR) using 11F and 12R primers as described previously.
6,7 PCR products were resolved on a 2% agarose gel (FMC, Rockland, ME, USA) stained with ethidium bromide.
Sequencing of longer PCR products
When an abnormal PCR product was obtained, it was confirmed by repeating PCR more than twice. Abnormal products were cloned into a pCR II plasmid vector (Invitrogen, San Diego, CA, USA) and sequencing was carried out using an automated DNA sequencing system (Model 373A; Applied Biosystems, Foster City, CA, USA).
Statistical analysis
All the statistical calculations were performed using a computer program, StatView J.4.5. (Abucus Concepts, Berkeley, CA, USA). The occurrence of tandem duplication in the JM domain of the FLT3 gene in childhood AML samples was compared with that of adult AML samples using the 2 test. Remission and total survival duration were studied by survival curves between children with mutant FLT3 and those with wild-type FLT3 according to the Kaplan-Meier method. Comparison between two survival curves was achieved by the generalized Wilcoxon test.
Results
Low frequency of FLT3 mutation in childhood AML
Tandem duplication of the FLT3 gene was screened by the results of electrophoresis (Figure 1 ). An abnormal PCR product was observed in 5/94 (5.3%) of all the children with AML ( Table 1 ). The frequency was significantly lower than that in adult patients (22/112; 19.6%) described in our previous report (P Ͻ 0.05) ( Table 1) . 7 
Independence of mutation of the FLT3 gene
The five patients with mutant FLT3 were classified as M0, M1, M2, M3 and M5 (Table 1) . Age, sex, peripheral blood cell count, LDH, and extra-medullary lesion (central nervous lesion, hepatomegaly, splenomegaly and lymphadenopathy) were unrelated to the mutation of the FLT3 gene, and there was no dominance between patients with wild-type FLT3 and those with mutant FLT3 (Table 2 ). No karyotype of the patients with mutant FLT3 included t(8;21), inv(16), t(9;11), or an abnormality of 11q23 (Table 3) . Figures 2 and 3 show the sequence structure of mutant FLT3. In all five patients, tandem duplications involved only exon 11. All the lengthened sequences were in-frame, and could be translated into amino acids (Figure 2 ). The amino acid (AA) sequence of the tandem-duplicated regions was restricted in the JM domain, and the initial part of the AA sequence of the TK1 domain was the same as that in the wild type (Figure 3 ). In our previous report, we presumed two putative phosphorylation sites, YFYV and YEYDLK, in the JM domain of FLT3. 7 In the duplicated regions of the present cases, YFYV was found in all cases, and YEYDLK in four cases.
Sequence of tandem-duplicated regions of the FLT3 gene
Poor prognosis of childhood AML patients with mutant FLT3
Disease-free survival (DFS) was studied by comparing survival curves (Kaplan-Meier method) by the generalized Wilcoxon test. DFS was defined as the duration from first diagnosis to first relapse or death including that in complete remission, but not stem cell transplantation. The results are shown in Figure  4 . In all cases DFS time was significantly shorter in children with mutant FLT3 than in those with wild-type FLT3 (P Ͻ 0.05) (Figure 4a ). The same results were obtained in all cases except M3 (Figure 4b ). Relapse occurred in two cases with tandem duplication of the FLT3 gene, and the total survival duration was less than 2 years in three cases (Table 3) .
Discussion
In this study we clarified the frequency of tandem duplication of the FLT3 gene and its significance as a factor of poor prognosis in childhood AML patients. In our recent studies of adults with hematological malignancies, we found that: [7] [8] [9] (1) the mutation of the FLT3 gene is restricted in AML and MDS; (2) mutant FLT3 is observed in about 20% of adult AML patients; (3) tandem duplicated regions of the gene are restricted in the JM domain; (4) sequences of the mutants are inframe. Using these data on adults for comparison, we evaluated our data on children in this report.
The prognosis of the cases with mutant FLT3 was significantly worse than that of the cases with wild-type FLT3. In childhood AML many prognostic factors have been reported; age, 15, 16 FAB subtype, 15, 17, 18 chromosomal abnormalities, 19 peripheral blood cell counts (WBC, Hb and PLT), 15, 16, 20 Auer rods, 17 extramedullary lesions, 15 terminal deoxynucleotidyl transferase (TdT), 21 surface markers 22, 23 and velocity of leukemic cell cycle. 24 However, some of these factors are still controversial. Existence of Auer rods has been reported both as a factor of poor prognosis 17 and of good prognosis. 20, 25, 26 In one previous study even FAB subclass was not a statistically significant prognostic factor. 26 In the present study we evaluated that mutation of the FLT3 gene was independent of these prognostic factors, and that patients with this mutation had a very poor prognosis.
It is puzzling that the frequency of the mutation was significantly lower in children than in adult patients. As one of the possible mechanisms, we considered a genomic instability. Chromosomal analyses of cases 8, 18 and 39 did not reveal typical structural abnormalities, but numerical abnormalities were found in cases 8 and 18 (Table 3 ). In our previous study, 2/3 of adults with mutant FLT3, whose karyotype could be examined, had not only structural abnormalities, but also some additional numerical abnormalities. 6 In another study, we reported that evolutional elongation of the duplicated region correlated with leukemic change in one adult MDS patient. 9 These facts might be due to some genomic instability of leukemic cells in AML and hematopoietic cells in MDS, leading to additional genomic disorders, which occurs more frequently in children than in adults. However, mutations of the N-ras and K-ras genes occurred as frequently in childhood AML as in adult AML. 27, 28 Microsatellite instabilities have not been studied in childhood AML as yet. This Sequence structure of the tandem duplicated regions. All the duplicated regions involved only exon 11.
Figure 3
AA sequence of the tandem-duplicated regions. The regions are shown in bold, and the second duplicated sequence in italics. In the duplicated regions putative autophosphorylation residues (YFYV and YEYDLK, underlined in black and dashed line, respectively) were increased. AA sequence of the TK1 domain was not hindered in any case.
issue requires more discussion when the number of cases with mutant FLT3 is sufficient to evaluate.
In this study on childhood AML, the sequence of length mutation of the FLT3 gene involved only the JM domain, and was in-frame as described in the previous studies on adult AML. 7 This suggests that mutation of the FLT3 in children with AML occurs in the same manner as in adults.
In conclusion, our results imply that tandem duplication of the FLT3 gene is an infrequent phenomenon but is a candidate factor of poor prognosis in childhood AML. Shuzo, Shiga, Japan) for sequencing and S Kaihara for careful reading of this manuscript.
